Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta‐analysis
Pooled result · Urine albumin-to-creatinine ratioResult — go to the resultMD −26.9 % 95% CI −34.76 to −19.04Authors' conclusion
Our findings suggest that tirzepatide probably leads to a significant reduction in albuminuria across all administered doses, while its use is associated with a neutral effect on creatinine clearance as a measure of renal function.
Study context
- Population
- Patients with T2D in published randomized controlled trials (RCTs); Medline, Cochrane Library and Scopus searched until 20 October 2023
- Participants
- 9,533 patients8 RCTs
- Comparison
- Tirzepatide vs controls
- Outcome
- Urine albumin-to-creatinine ratio
Methodological detailsthree-level mixed-effects meta-analysis, double-independent study selection, All RCTs had low risk of bias (RoB2)
- Three-level mixed-effects meta-analysis
- Double-independent study selection
- All RCTs had low risk of bias (RoB2)
Pooled result
As reported in the abstract
MD
−26.9 %
95% CI −34.76 to −19.04
P < 0.001
Tirzepatidevs Controls
MD −26.9 % (95% CI −34.76 to −19.04); P < 0.001
Further pooled results
UACR in participants with baseline UACR ≥30 mg/g
- Effect remained significant in participants with baseline UACR ≥30 mg/g; MD (%), 95% CI, P
- −41.42%; (−54.38, −28.45); p < .001
- Level of evidence (LoE) moderate
UACR by comparator (subgroup analysis)
- Comparative effect of tirzepatide significant vs placebo and insulin regimen; no difference vs semaglutide
Albuminuria by tirzepatide dose
- Beneficial effect remained significant across all doses (5, 10 and 15 mg), with a dose-response relationship
eGFR
- Neutral effect on eGFR; MD, 95% CI, P
- 0.39 ml/min/1.73m2; (−0.64, 1.42); p = .46
- LoE moderate
Original publication
Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta‐analysis. Diabetes Obes Metab. Published 20 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →